Company news
Palisade Bio, Inc. news in 2025
Palisade Bio, Inc.'s news releases, calls and decks from 2025, newest first.
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
December 30, 2025
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
December 2, 2025
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
October 28, 2025
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
October 20, 2025
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
October 13, 2025
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
October 9, 2025
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
October 2, 2025
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
October 1, 2025
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
September 26, 2025
Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
September 17, 2025
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
September 5, 2025
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
August 25, 2025
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
August 7, 2025
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
July 31, 2025
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
July 23, 2025
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
July 22, 2025
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
July 9, 2025
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
May 27, 2025
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
May 6, 2025
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
May 1, 2025
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
April 9, 2025
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
March 14, 2025
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
March 12, 2025
Palisade Bio Participates in Virtual Investor “What This Means” Segment
March 4, 2025
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
February 20, 2025
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
February 9, 2025
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
January 15, 2025
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 2, 2025
Decks in 2025
- STAR Annual Meeting 2025
Conference · 18 slides · September 2025